If you are reading this, you have probably already heard that a dog dewormer can cure cancer. Or that a diabetes pill is quietly starving tumors. Or that cholesterol drugs might secretly be “the new chemo.” Social media and search results are full of confident claims about metformin, statins, doxycycline, mebendazole/fenbendazole.
The result is not calm or clarity. It is overwhelming noise.
If you are living with cancer or caring for someone who is, that noise can feel urgent. What if one of these really is the missing piece?
This article is to attempt to answer a simple question: What does the science actually say?
Important: This article is for education only. It cannot replace personal medical advice. Do not start, stop, or change any medication without talking with your oncology team.
What “Drug Repurposing” Really Means in Cancer
Drug repurposing means using an existing medication for a disease it was not originally approved to treat. Groups like Every Cure (ROADMAP Project) are trying to systematize this work by mapping which approved drugs might help in other diseases, then testing them rigorously so we can tell apart genuine signal from “snake oil” more quickly and fairly.
In cancer care, repurposing usually looks like taking a drug used for something else (in this note: diabetes, cholesterol, infections, or worms) and testing it as a helper alongside standard treatments, or as a preventive tool, or, rarely, as a standalone treatment.
It is appealing because:
These drugs are often inexpensive generics.
We already understand their usual doses and side effects.
They target pathways like metabolism, inflammation, and blood vessel growth, which cancer cells also rely on.
At the same time, for all five drugs discussed here, major oncology guidelines view them, at best, as experimental add ons, not standard stand alone cancer treatments.
So, are these repurposed drugs actually helpful, and if so, how much?
The Big Picture: What We Know So Far
Overall pattern
Across metformin, statins, doxycycline, mebendazole, and fenbendazole, the overall pattern looks like this:
All have laboratory and early clinical data suggesting anticancer potential.
Patient stories about them are everywhere.
None are established standard cancer treatments, and the strength of evidence varies by drug and cancer type.
Strength of human data
You can think of the strength of human data as three tiers:
Metformin and statins: strongest evidence, mostly modest relative risk reductions from large observational studies and some adjunctive trials.
Doxycycline and mebendazole: good lab data but only small, mixed early phase human studies.
Fenbendazole: mainly case reports and animal work, with no controlled human trials or quantifiable survival benefit.
Size and scope of benefit
No drug has disease wide randomized data showing large survival gains.
When benefits are seen, they are generally modest and highly cancer- and context-specific.
Key caveats
Most of the research comes from “watching what happens” in real life or from small early studies, so the benefits can easily look bigger on paper than they really are in everyday practice.
Almost all studies use these drugs in addition to standard therapy, not instead of it.
Safety and interaction issues
Before going any further, we need to talk about safety, which most of the trendier posts tend to skip.
Cancer patients are often:
On multiple medications: chemotherapy, targeted drugs, immunotherapy, anticoagulants, anti-nausea drugs, pain medicines, and more.
Living with organ stress from both the cancer and its treatment.
Even well known, older drugs can add real risk.
Metformin
Can cause low blood sugar in the wrong setting (poor oral intake, other diabetes meds).
Rarely, can trigger lactic acidosis, especially with advanced kidney, liver, or heart failure.
Commonly causes GI upset (nausea, diarrhea, cramping), which can be rough on people already struggling to eat.
Long term use can contribute to vitamin B12 deficiency, which may worsen fatigue or neuropathy.
Needs dose adjustment or discontinuation with kidney impairment, severe dehydration, or contrast imaging in some cases.
Statins
Can cause muscle aches and weakness, and in rare cases serious muscle injury or rhabdomyolysis.
Can raise liver enzymes and occasionally cause clinically significant liver injury.
May slightly increase the risk of new-onset diabetes in susceptible people.
Have important drug–drug interactions (for example, via CYP3A4) with some chemo, TKIs, antifungals, and antibiotics, which can raise statin or partner drug levels.
Can occasionally cause cognitive or sleep complaints (brain fog, vivid dreams) in sensitive patients.
Doxycycline
Commonly causes GI upset (nausea, reflux, diarrhea) and can cause pill-related esophagitis if not taken with enough water or if the person lies down right away.
Disrupts gut flora and can increase risk of yeast infections or C. difficile diarrhea in vulnerable patients.
Increases sun sensitivity, adding to skin risk during radiation or targeted therapies that already affect skin.
Can very rarely affect liver function or trigger hypersensitivity reactions.
Interacts with some anticoagulants and other meds, which may require dose adjustments.
Mebendazole and fenbendazole
Can stress the liver and, at higher or prolonged doses, have been linked to clinically significant hepatotoxicity.
May cause GI side effects (abdominal pain, nausea, diarrhea) and allergic reactions.
At high or prolonged doses, benzimidazoles have been associated with bone marrow suppression in some contexts, which is concerning in patients already cytopenic from chemo.
Have unpredictable absorption and metabolism, especially at non-standard doses, making blood levels hard to estimate.
May interact with other drugs processed by the same liver pathways (including some chemo, targeted therapies, and antifungals), potentially changing drug levels and toxicity in either direction.
In cancer care, stacking these risks on top of existing treatment can show up as:
Worsening liver toxicity (especially with preexisting liver disease or other liver-stressing drugs).
Kidney issues, especially when dehydration, contrast dye, or nephrotoxic chemo are also in play.
Heart rhythm changes (QT prolongation) with certain combinations.
Altered levels of chemotherapy, immunotherapy, or targeted agents, leading to either under-treatment or more side effects than expected.
Any off-label drugs for cancer should be done in partnership, not in the shadows. Talk about it directly with your oncology team, and ensure you have a provider to monitor labs, side effects and progress along the way. If you need help finding a provider who is willing to have this conversation, or language to start it, I am always happy to help. You can visit drkseniamalarkey.com to schedule a free 10 minute consultation.
My clinical experience
Many medical oncologists reading this will probably cringe when I say that roughly 90% of my integrative oncology patients are either already taking some combination of repurposed drugs or actively asking about them. In my experience, simply saying “these do not work, stop everything” almost never works.
In practice, I frequently end up reviewing doses that patients have started on their own or that appear in the literature and other clinicians’ protocols. For example, a common range might be:
Mebendazole: 112 mg or 224 mg daily, with meals
Metformin: 500–1000 mg twice a day, with meals
Doxycycline: 100–200 mg daily
Atorvastatin: 40–80 mg at bedtime
These are not recommendations for self-prescribing. They are context for how these drugs sometimes show up in clinical conversations.
Do I see these agents as cure alls or as the foundation of integrative cancer care? No.
It is, however, core to my practice to individualize every treatment plan, carefully weigh risks and potential benefits, and then make a shared, informed decision with the patient about whether prescribing one of them makes sense in their specific situation.
I most often consider repurposed drugs in the following cancer types: metformin in colorectal, breast, endometrial, and pancreatic cancers; statins in hepatocellular carcinoma, breast cancer, lung cancer, and multiple myeloma; doxycycline in breast and some solid tumors with a strong cancer stem cell component; and mebendazole in select colorectal and high grade brain tumors. These are not magic bullets, but I have seen these drugs make a real, trackable (scans, labs, and ctDNA) difference for some patients.
As a provider, and as a “difficult patient,” I like to understand the weeds, not just the headlines – so in the next section we’ll go there together and look closely at what we actually know about each drug.